LFCR

Lifecore Biomedical, Inc.
CAPPED RATING

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. It operates through Lifecore, Curation Foods, and Other segments. The Lifecore segment engages in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, including technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. This segment sells its non-HA products for medical use primarily in the ophthalmic, orthopedic, and other markets. The Curation Foods segment engages in processing, marketing, and selling of olive oils and wine vinegars under the O brand; and guacamole and avocado food products under the Yucatan and Cabo Fresh brands, as well as various private labels. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was incorporated in 1986 and is headquartered in Santa Maria, California.

Lifecore Biomedical, Inc. (LFCR) is rated C- (1.9/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B+); its weakest is Revisions (F). The rating has held at C- for 2 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
1.9 / 5.0
C-
Value
D+
Factor Score 1.5 / 5.0
Growth
D+
Factor Score 1.8 / 5.0
Profitability
C+
Factor Score 2.5 / 5.0
Momentum
B+
Factor Score 3.8 / 5.0
Revisions
F
Factor Score 0.0 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -8.9
EV / EBITDA 103.8
Rev Growth YoY -18.6%
Gross Margin 27.5%
Price Return 3M 35.6%
Price Return 12M -17.3%
Catalyst Signal 0.00
Market Cap $242.6M
TTM Revenue $106.5M
Price / Sales 2.3
ROE N/A

Historical Factor Score Progression

Held C- for 2 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-13 D+ (1.5) D+ (1.8) C+ (2.5) B+ (3.8) F (0.0) C- (1.9)
2026-11-06 D+ (1.5) C- (1.9) C (2.2) B+ (3.8) F (0.0) C- (1.9)
2026-10-30 C- (1.9) C- (2.1) C+ (2.6) B+ (3.7) F (0.0) C- (2.1)
2026-10-23 C- (1.9) C- (1.9) C+ (2.6) C+ (2.8) F (0.0) D+ (1.8)
2026-10-16 C- (1.9) C- (1.9) C+ (2.6) C+ (2.7) F (0.0) D+ (1.8)
Page 1 of 4